^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    shIDO-ST

    i
    Other names: shIDO-ST, salmonella-based cancer therapeutics, shIDO ST
    Associations

    News

    Trials
    Company:
    Tara I-O
    Drug class:
    IDO inhibitor
    Related drugs:
    Associations

    News

    Trials
    4years
    Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. (PubMed, Biomedicines)
    These results suggest that the success of ICB therapy may be more accurately predicted by taking into account multiple factors such as potential for antigen presentation and immune subset repertoire in addition to markers already being considered. Alternatively, combination treatment with agents such as shIDO-ST could be used to create a more conducive tumor microenvironment for improving responses to ICB.
    Clinical • Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
    |
    shIDO-ST